MUMBAI (Reuters) - Indian drugmaker Dr Reddy's Laboratories Ltd said on Friday it has received final approval from the U.S. Food and Drug Administration (FDA) to make a cheaper version of Roche Holding AG's antiviral Valcyte, sending its stock to a record high.
The move comes after Ranbaxy Laboratories Ltd said on Thursday that FDA had stripped the company of its tentative approval to launch the first copy of the drug due to quality control issues at its manufacturing plants.
19:34 CEO shift at Coca-Cola could usher in more dealmaking to refresh soda giant's growth10
16:37 Fitbit acquires software assets from rival Pebble13
14:31 Lost Christmas parcels 'prompt two-and-a-half-hour hunt'16
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff19